K562-mb-IL15-41BBL activated and expanded NK cells

K562-mb-IL15-41BBL activated and expanded NK cells are an adoptive cell therapy product consisting of Natural Killer (NK) cells that have been stimulated and proliferated *ex vivo*. The manufacturing process utilizes a genetically modified K562 leukemia cell line as "feeder cells," which have been engineered to express membrane-bound Interleukin-15 (mbIL15) and 4-1BB ligand (4-1BBL; CD137L). These two signals are crucial: mbIL15 promotes the survival and expansion of NK cells, while 4-1BBL provides a potent costimulatory signal that enhances their cytotoxic activity and longevity. This expansion method can produce a high yield of pure, highly active NK cells from either autologous (patient-derived) or allogeneic (donor-derived) sources. Once infused into the patient, these expanded NK cells target malignant cells through a variety of activating receptors (such as NKG2D and natural cytotoxicity receptors) and can mediate antibody-dependent cellular cytotoxicity (ADCC) if combined with monoclonal antibodies. This therapy is primarily being investigated for the treatment of hematologic malignancies like acute myeloid leukemia (AML) and various solid tumors.

Other names

mbIL15/4-1BBL expanded NK cellsK562-stimulated NK cellsK-562-stimulated NK cellsK 562-stimulated NK cellsK562-mbIL15-41BBL-NKK-562-mbIL15-41BBL-NKK 562-mbIL15-41BBL-NK